KAI Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in the areas of cardiovascular disease, kidney disease and pain. KAI lead product candidate, KAI-9803, is currently in a Phase 2b study (PROTECTION AMI) designed to assess the effect of KAI-9803 on reducing myocardial injury in heart attack patients. KAI second core program, KAI-4169 for the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients, is expected to enter human clinical trials in 2010. KAI also has an ongoing pain program, KAI-1678, which is currently in Phase 2a testing.
Current Team (1)Update
Founder / CSO / Scientific Consultant / Chairperson, Scientific Advisory Board Director
Past Team (4)Update
Board Members and Advisors (2)Update
Venture capital Firm
Venture Capital Firm
Skyline Ventures, formed in 1997, is a nationally-known venture capital firm that specializes in...
InterWest invests an average of about $7 - 15 million over the span of their involvement with...
Intersouth Partners is one of the most active and experienced venture funds in the Southeast,...
270 Littlefield Avenue
South San Francisco, CA 94080
- 07/05/12 -delphiventures.com